Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife
CyberKnife Centers Are Meeting Increasing Demand for Radiosurgery Using Sophisticated Treatment Planning and Delivery Technologies
The next generation CyberKnife System was installed at Philadelphia CyberKnife, a US Radiosurgery center, in
“With the new planning system, Iris collimator and the new delivery path found in the next generation CyberKnife System, we can design better treatment plans, track moving tumors more precisely and can deliver planned doses more efficiently, which shortens patient treatment times,”
The significant improvements in treatment times that Philadelphia CyberKnife is noticing with the next generation System are making the treatment experience even more comfortable and convenient for patients. Compared to the 40 outpatient visits commonplace with conventional radiation therapy, CyberKnife treatments are completed in just one to five visits.
The next generation CyberKnife System incorporates a number of sophisticated technologies to achieve a considerable reduction in treatment times, enabling hospitals and centers to treat more patients. Currently Philadelphia CyberKnife is treating the full range of applications including brain, spine, lung, liver, prostate and pancreas, with approximately 70 percent of treatments for extracranial indications and the other 30 percent intracranial.
The CyberKnife System enables clinicians to treat of a whole new group of patients including those with inoperable or surgically complex tumors or patients who were deemed medically inoperable. Treating this new population that couldn’t traditionally be treated with radiation therapy alone provides hospitals a new revenue stream.
“With the addition of a CyberKnife System, hospitals and centers are able to treat patients that they would have once needed to turn away or relegate to a less optimal form of treatment,” said
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to commercialization of products, clinical studies, and regulatory review and approval are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q filed on
SOURCE Accuray Incorporated